Monophasic, cohesive-polydensified-matrix crosslinking-technology-based hyaluronic acid filler for the treatment of facial lipoatrophy in HIV-infected patients

Journal of Drugs in Dermatology

Volumn 9, Issue 6, 2010, Pages 690-695

  Pavicic, Tatjana ^a   Ruzicka, Thomas ^a   Korting, Hans Christian ^a   Gauglitz, Gerd ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BELOTERO BASIC; BENZATHINE; HYALURONIC ACID; UNCLASSIFIED DRUG; CROSS LINKING REAGENT;

ADULT; ARTICLE; CASE REPORT; CHLAMYDIA TRACHOMATIS; CONSULTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MALE; MYCOPLASMA; NEISSERIA GONORRHOEAE; SCORING SYSTEM; SYPHILIS; SYRINGE; FACE; HIV ASSOCIATED LIPODYSTROPHY; MIDDLE AGED;

ADULT; CROSS-LINKING REAGENTS; FACE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED;

EID: 77955884347     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;7:F51-58. (Pubitemid 28190689)
2. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;21:871-875. (Pubitemid 28121176)
3. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther. 2004;9:555-564. (Pubitemid 39150213)
4. McComsey GA, Walker UA. Role of mitochondria in HIV lipoatrophy: Insight into pathogenesis and potential therapies. Mitochondrion. 2004;4:111-118. (Pubitemid 39549800)
5. Borderi M, Verucchi G, Tadolini M, et al. Metabolic complications of HIV-1 antiretroviral therapy: The lipodystrophy syndrome. New Microbiol. 2001;24:303-315. (Pubitemid 33633227)
6. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000;10:546-550.
7. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS. 2001;7:2441-2444. (Pubitemid 34014613)
8. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: A three-year randomized trial. JAMA. 2004;292:191-201. (Pubitemid 38917996)
9. Bergersen BM, Sandvik L, Ellingsen I, Bruun JN. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive. HIV Med. 2005;6:260-267. (Pubitemid 41025291)
10. Carruthers A, Carruthers J. Non-animal-based hyaluronic acid fillers: Scientific and technical considerations. Plast Reconstr Surg. 2007;120:33S-40S. (Pubitemid 350306744)
11. Falcone SJ, Berg RA. Crosslinked hyaluronic acid dermal fillers: A comparison of rheological properties. J Biomed Mater Res A. 2008;87:264-271.
12. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316. (Pubitemid 30459502)
13. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-979. (Pubitemid 36549708)
14. Dirting K, Lampe H, Wolters M, et al. Hyaluronic acid filler for correction of nasolabial grooves--results of a clinical study. J Dtsch Dermatol Ges. 2008;6:S10-14. (Pubitemid 351999753)
15. Levan P, Nguyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS. 2002;16:1985-1987.
16. Moyle GJ, Brown S, Lysakova L, Barton SE. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med. 2006;7:181-185. (Pubitemid 43337597)
17. Mest DR, Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The U.S. experience. Dermatol Surg. 2006;32:1336-1345. (Pubitemid 44691136)
18. Levy RM, Redbord KP, Hanke CW. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: A prospective three-year follow-up study. J Am Acad Dermatol. 2008;59:923-933.
19. Carey D, Baker D, Petoumenos K, et al. Poly-L-lactic acid for HIV-1 facial lipoatrophy: Forty-eight-week follow-up. HIV Med. 2009;10:163-172.
20. Ascher B, Coleman S, Alster T, et al. Full scope of effect of facial lipoatrophy: A framework of disease understanding. Dermatol Surg. 2006;32:1058-1069. (Pubitemid 44197458)
21. Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-L-lactic acid). J Drugs Dermatol. 2004;3:542-547.
22. Borelli C, Kunte C, Weisenseel P, et al. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol. 2005;18:273-278. (Pubitemid 41527617)
23. Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: One-year durability. Plast Reconstr Surg. 2006;118:34S-45S. (Pubitemid 44319089)
24. Bugge H, Negaard A, Skeie L, Bergersen B. Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients. HIV Med. 2007;8:475-482. (Pubitemid 47616825)
25. Reytan N, Rzany B. A ribose-crosslinked collagen filler treatment for facial lipoatrophy associated with the treatment of human immunodeficiency virus. J Drugs Dermatol. 2008;7:1169-1171.